New Research at SLEEP 2013 Demonstrates People with Narcolepsy Face Significant Health and Economic Burden and High Rates of

     New Research at SLEEP 2013 Demonstrates People with Narcolepsy Face
    Significant Health and Economic Burden and High Rates of Misdiagnosis

  PR Newswire

  DUBLIN, June 5, 2013

-- First U.S. study to highlight severe comorbidities and economic burden
associated with narcolepsy

-- Survey indicates some sleep specialists may not be comfortable diagnosing

-- Patients' journeys survey shows narcolepsy diagnosis involves multiple
physician visits and misdiagnoses

DUBLIN, June 5, 2013 /PRNewswire/ -- Researchers will present data today that
demonstrate people with narcolepsy face significant personal health and
economic burden. The Burden of Narcolepsy Disease (BOND) study, the largest of
its kind and the first in the United States, found that patients with
narcolepsy, with or without cataplexy, were more likely to suffer from a
higher frequency of comorbidities such as mental illness, endocrine disorders,
digestive disorders and cardiovascular disease, and had more than twice the
mean annual medical costs compared with the general population. These data,
supported by Jazz Pharmaceuticals plc (Nasdaq: JAZZ), will be presented at
SLEEP 2013, the annual meeting of the Associated Professional Sleep Societies
LLC (APSS) taking place this week in Baltimore, Md.

Additional results from two surveys presented at SLEEP characterize the impact
that narcolepsy, as a currently misunderstood and underdiagnosed medical
condition, has on patient care. The Awareness and Knowledge in Narcolepsy
(AWAKEN) survey found that almost a quarter of 100 sleep specialists and more
than half of 300 primary care physicians surveyed are not comfortable
diagnosing narcolepsy. Results from the Patients' Journeys to a Narcolepsy
Diagnosis survey of physicians characterize the many challenges patients must
overcome and indicate that patients often go through multiple misdiagnoses and
physician visits before reaching an accurate narcolepsy diagnosis.

"Jazz Pharmaceuticals plc continues to support ongoing narcolepsy research,
such as BOND and AWAKEN, and hopes that awareness of the data presented at
SLEEP will help sleep specialists, physicians and the general public better
understand narcolepsy as a serious disabling medical condition," said Jed
Black, M.D., Vice President, Sleep Medicine, Jazz Pharmaceuticals and
Consulting Associate Professor, Stanford University Medical Center, Stanford
Center for Sleep Sciences and Medicine.

The Burden of Narcolepsy Disease (BOND) Study The purpose of the BOND study
was to examine comorbidities associated with narcolepsy and the burden of
these diseases on patients. As part of the protocol for the study, researchers
evaluated the Truven Health Analytics MarketScanĀ® Research Databases, which
consist of more than 50 million patients across the United States, to identify
a group of more than 9,000 narcolepsy patients each with at least five
consecutive years of healthcare data, and matched these patients to more than
46,000 control patients. Jazz Pharmaceuticals sponsored the BOND study, but
was not involved in the study design, analysis or scientific representation.
The study investigators were not compensated by Jazz Pharmaceuticals.

Given the robust set of data from the BOND study, researchers reported the
results in four abstracts presented at SLEEP, including:

  *High Rates of Psychiatric Comorbidity in Narcolepsy : Patients with
    narcolepsy had significantly higher frequency of anxiety and mood
    disorders, and a higher rate of psychiatric medication usage compared with
    the non-narcolepsy population. [Abstract 0904]
  *High Rates of Medical Comorbidity in Narcolepsy : Narcolepsy patients had
    significantly higher frequencies of respiratory, musculoskeletal,
    endocrine and circulatory conditions across the five-year period when
    compared with control subjects. [Abstract 0723]
  *Burden of Illness and Comorbidity in Narcolepsy with Cataplexy : Patients
    who have narcolepsy with cataplexy showed significantly higher rates of
    healthcare utilization and higher frequencies of sleep apnea,
    cardiovascular disease and pulmonary conditions compared with the
    non-narcolepsy population. [Abstract 0725]
  *Healthcare Utilization and Costs in Narcolepsy : Narcolepsy patients had
    approximately two-fold higher annual rates of hospital admissions and
    physician visits compared with control subjects. [Abstract 0724]

"While the medical community knows that narcolepsy is associated with
significant medical comorbidities, BOND is the first study to use U.S.
longitudinal patient data to validate the full scope of concomitant illness,"
said Dr. Chad Ruoff, Clinical Assistant Professor, Stanford University Medical
Center, Stanford Center for Sleep Sciences and Medicine. "The data provide
further insight into the impact of narcolepsy on patients and our healthcare
system, and suggest how important early diagnosis and regular screening are in
reducing this burden."

The AWAKEN Survey: Physician Knowledge and Diagnosis of Narcolepsy [Abstract
0730] This online survey of 1,000 adults, 300 primary care physicians (PCPs)
and 100 sleep specialists conducted by Jazz Pharmaceuticals and Harris
Interactive found that physicians struggle with narcolepsy symptom recognition
and diagnosis. Only nine percent of PCPs and 42 percent of sleep specialists
reported that they are comfortable diagnosing narcolepsy, and 22 percent of
sleep specialists reported they are "not very or not at all comfortable"
diagnosing the disorder.

Patients' Journeys to a Narcolepsy Diagnosis [Abstract 0738] More than 75
expert neurologists, pulmonologists, psychiatrists and other board certified
sleep specialists who treat at least five narcolepsy patients per month
completed a survey using data from the charts of 252 narcolepsy patients. The
survey aimed to provide insight into the patient's journey to diagnosis for
narcolepsy. Jazz Pharmaceuticals conducted the survey and found that 60
percent of patients had been misdiagnosed with other disorders, such as
depression, insomnia and/or obstructive sleep apnea, before receiving the
appropriate narcolepsy diagnosis, additionally 67 percent of patients saw
multiple providers prior to receiving a narcolepsy diagnosis.

"Approximately half of the patients living with narcolepsy go undiagnosed or
are misdiagnosed, and many live with the disorder for 10 years before they
receive a correct diagnosis," said Russell Rosenberg, PhD, primary author of
AWAKEN, director and chief scientist at NeuroTrial Research and current
chairman of the National Sleep Foundation. "Findings from the AWAKEN survey,
and more research like this, will help us better understand current physician
misperceptions that may contribute to a patient's journey, and hopefully
create more urgency around the need for enhanced narcolepsy screening and

About Narcolepsy Narcolepsy is a serious, chronic disorder of the central
nervous system characterized by symptoms of excessive daytime sleepiness
(EDS), muscle weakness (cataplexy), disrupted nighttime sleep, hypnagogic
hallucinations and sleep paralysis. People with narcolepsy experience abrupt
shifts between wakeful and REM-like states that are thought to be caused by a
loss or impairment of hypocretin-producing neurons in the hypothalamus. The
disorder affects approximately one in 2,000 Americans, yet approximately 50
percent of patients remain undiagnosed. Symptoms of narcolepsy often start
between the ages of 15 and 25.

Jazz Pharmaceuticals Commitment to Narcolepsy Jazz Pharmaceuticals is
dedicated to working with patients, researchers, providers and advocacy
organizations to further the awareness, understanding and improved diagnosis
of narcolepsy, and to helping the narcolepsy community navigate the
complexities associated with the disorder. As part of this commitment, Jazz
Pharmaceuticals supports initiatives and research to improve narcolepsy
awareness and to help the sleep community address the misunderstanding,
misperceptions and misdiagnosis surrounding the disease.

AboutJazz Pharmaceuticals Jazz Pharmaceuticalsplcis a specialty
biopharmaceutical company focused on improving patients' lives by identifying,
developing and commercializing innovative products that address unmet medical
needs. The company has a diverse portfolio of products in the areas of
narcolepsy, oncology, pain and psychiatry. For further information, see .

Contact: Investor, Kathee Littrell, Vice President, Investor Relations, Jazz
Pharmaceuticals plc, Ireland, +353 1 634 7887, U.S., + 1 650 496 2717; Media,
Laurie Hurley, Vice President, Corporate Affairs, Jazz Pharmaceuticals plc,
Ireland, +353 1 634 7894, US, +1 650 496 2796
Press spacebar to pause and continue. Press esc to stop.